Advances in Radiotherapy for Rectal Cancer

Timothy Lin; Amol Narang

doi:10.1016/j.soc.2023.02.003

Advances in Radiotherapy for Rectal Cancer

Surg Oncol Clin N Am. 2023 Jul;32(3):461-473. doi: 10.1016/j.soc.2023.02.003. Epub 2023 Apr 4.

Authors

Timothy Lin¹, Amol Narang²

Affiliations

¹ Department of Radiation Oncology & Molecular Radiation Sciences, Johns Hopkins University School of Medicine, 401 N Broadway, Baltimore, MD 21287, USA.
² Department of Radiation Oncology & Molecular Radiation Sciences, Johns Hopkins University School of Medicine, 401 N Broadway, Baltimore, MD 21287, USA. Electronic address: anarang2@jhmi.edu.

PMID: 37182987
DOI: 10.1016/j.soc.2023.02.003

Abstract

The current preferred standard of care management for patients with locally advanced rectal cancer is total neoadjuvant therapy, in which all chemotherapy and radiotherapy is delivered before surgery. Within this approach, developed in response to persistently high distant failure rates despite excellent local control with preoperative chemoradiotherapy, there remains questions regarding the optimal radiotherapy regimen (short course vs long course) and sequencing of chemotherapy (induction vs consolidation).

Keywords: Nonoperative management; Rectal adenocarcinoma; Short-course radiotherapy; Total neoadjuvant therapy; Watch-and-wait.

Publication types

Review

MeSH terms

Chemoradiotherapy
Humans
Neoadjuvant Therapy
Neoplasm Recurrence, Local* / drug therapy
Rectal Neoplasms* / radiotherapy
Rectal Neoplasms* / surgery
Treatment Outcome